These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23359557)

  • 1. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.
    Zobell JT; Young DC; Waters CD; Ampofo K; Stockmann C; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Jun; 48(6):525-37. PubMed ID: 23359557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones.
    Stockmann C; Sherwin CM; Zobell JT; Young DC; Waters CD; Spigarelli MG; Ampofo K
    Pediatr Pulmonol; 2013 Mar; 48(3):211-20. PubMed ID: 22949224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
    Zobell JT; Waters CD; Young DC; Stockmann C; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Feb; 48(2):107-22. PubMed ID: 22949297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems.
    Zobell JT; Young DC; Waters CD; Stockmann C; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2012 Dec; 47(12):1147-58. PubMed ID: 22911974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium.
    Young DC; Zobell JT; Waters CD; Ampofo K; Stockmann C; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Jan; 48(1):1-7. PubMed ID: 22949160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on treatment of pulmonary exacerbations in cystic fibrosis.
    Smyth A
    Curr Opin Pulm Med; 2006 Nov; 12(6):440-4. PubMed ID: 17053495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion meropenem and ticarcillin-clavulanate in pediatric cystic fibrosis patients.
    Zobell JT; Ferdinand C; Young DC
    Pediatr Pulmonol; 2014 Mar; 49(3):302-6. PubMed ID: 23775821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients.
    Zobell JT; Young DC; Waters CD; Ampofo K; Cash J; Marshall BC; Olson J; Chatfield BA
    Pediatr Pulmonol; 2011 Oct; 46(10):987-90. PubMed ID: 21520438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic use in cystic fibrosis.
    Eisenberg JD
    Curr Opin Pulm Med; 1996 Nov; 2(6):439-46. PubMed ID: 9363182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of doripenem in pediatric cystic fibrosis patients in case of meropenem shortages.
    Zobell JT; Kemper AL; Young DC
    Pediatr Pulmonol; 2014 Mar; 49(3):E48-51. PubMed ID: 23661625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients.
    Cies JJ; Varlotta L
    Pediatr Pulmonol; 2013 Dec; 48(12):1190-4. PubMed ID: 23281228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a Pseudomonas aeruginosa eradication policy in a cystic fibrosis clinic.
    Davidson AG; Chilvers MA; Lillquist YP
    Curr Opin Pulm Med; 2012 Nov; 18(6):615-21. PubMed ID: 22990661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa and the airways disease of cystic fibrosis.
    Hata JS; Fick RB
    Clin Chest Med; 1988 Dec; 9(4):679-89. PubMed ID: 3148384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.
    Döring G; Conway SP; Heijerman HG; Hodson ME; Høiby N; Smyth A; Touw DJ
    Eur Respir J; 2000 Oct; 16(4):749-67. PubMed ID: 11106223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
    Elborn JS; Hodson M; Bertram C
    J Cyst Fibros; 2009 May; 8(3):211-7. PubMed ID: 19372063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management.
    Parkins MD; Elborn JS
    J Antimicrob Chemother; 2010 Sep; 65(9):1853-61. PubMed ID: 20605846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.